10-Q - BALCHEM CORP (0000009326) (Filer)

8-K - BALCHEM CORP (0000009326) (Filer)

8-K - BALCHEM CORP (0000009326) (Filer)

8-K - BALCHEM CORP (0000009326) (Filer)

10-Q - BALCHEM CORP (0000009326) (Filer)

8-K - BALCHEM CORP (0000009326) (Filer)

8-K - BALCHEM CORP (0000009326) (Filer)

11-K - BALCHEM CORP (0000009326) (Filer)

10-Q - BALCHEM CORP (0000009326) (Filer)

8-K - BALCHEM CORP (0000009326) (Filer)

MONTVALE, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will present at Baird's 54th Annual Global Industrial Conference on November 13, 2024. Ted Harris, Chairman of the Board, President and Chief Executive Officer, Martin Bengtsson, Chief Financial Officer and Allison Baurichter, Senior Director Investor Relations will present at the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and

MONTVALE, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2024 fiscal third quarter ended September 30, 2024. For the quarter, the Company reported net sales of $239.9 million, net earnings of $33.8 million, adjusted EBITDA(a) of $64.4 million, and free cash flow(a) of $42.2 million. Ted Harris, Chairman, President and CEO of Balchem said, "We delivered strong third quarter financials with solid revenue growth and record earnings from operations and adjusted EBITDA. We continue to see excellent performance in our Human Nutrition and Health and Specialty Products segments, both delivering strong sales and earnings g

MONTVALE, N.J., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Friday, October 25, 2024, at 11:00 AM Eastern Time (ET) to review third quarter results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Third quarter results will be published prior to the market opening on Friday, October 25, 2024. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. We invite you to listen to the conference by calling toll-free 1-877-407-8289 (local dial-in 1-201-689-8341), five m

MONTVALE, N.J., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will present at the HC Wainwright & Co. 26th Annual Global Investment Conference on September 9, 2024. Ted Harris, Chairman of the Board, President and Chief Executive Officer, Martin Bengtsson, Chief Financial Officer and Allison Baurichter, Senior Director Investor Relations will present at the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solut

MONTVALE, N.J., July 26, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2024 fiscal second quarter ended June 30, 2024. The Company reported quarterly net sales of $234.1 million, quarterly net earnings of $32.1 million, adjusted EBITDA(a) of $62.3 million, and free cash flow(a) of $38.4 million. Ted Harris, Chairman, President and CEO of Balchem said, "We delivered solid second quarter financials with record earnings from operations and adjusted EBITDA. I am particularly pleased with the excellent performance in our Human Nutrition and Health and Specialty Products segments, both delivering strong sales and earnings growth." Second Qu

MONTVALE, N.J., July 12, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Friday, July 26, 2024, at 11:00 AM Eastern Time (ET) to review second quarter results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Second quarter results will be published prior to the market opening on Friday, July 26, 2024. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. We invite you to listen to the conference by calling toll-free 1-877-407-8289 (local dial-in 1-201-689-8341), fi

MONTVALE, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will present at the CJS Securities 24th Annual New Ideas Summer Conference on July 10, 2024. Ted Harris, Chairman of the Board, President and Chief Executive Officer, Martin Bengtsson, Chief Financial Officer and Allison Baurichter, Senior Director Investor Relations will present at the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and t

MONTVALE, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will present at the Wells Fargo Industrials Conference on June 12, 2024. Ted Harris, Chairman of the Board, President and Chief Executive Officer, Martin Bengtsson, Chief Financial Officer, and Allison Baurichter, Senior Director Investor Relations will present at the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and the finest quality pr

MONTVALE, N.J., May 21, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will attend the Deutsche Bank Global Consumer Conference on June 4, 2024. Ted Harris, Chairman of the Board, President and Chief Executive Officer, and Martin Bengtsson, Chief Financial Officer will attend the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and the finest quality products for a range of industries worldwide. The company rep

MONTVALE, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2024 fiscal first quarter ended March 31, 2024. The Company reported quarterly net sales of $239.7 million, quarterly net earnings of $29.0 million, adjusted EBITDA(a) of $60.9 million, and free cash flow(a) of $26.8 million. Ted Harris, Chairman, President and CEO of Balchem said, "The first quarter was a very good start to the year for Balchem. We delivered record net sales, adjusted EBITDA, and net earnings, as well as solid first quarter cash flows, despite the continued challenging environment in parts of our portfolio." First Quarter 2024 Financial Hig

BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal (GI) diseases, today announced the appointment of Terry Coelho to its Board of Directors effective immediately. The appointment increases the size of AzurRx's Board to seven members. Ms. Coelho currently serves as the Executive Vice President and Chief Financial Officer at BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a commercial-stage specialty pharmaceutical company. During her more than 30-year career, Ms. Coelho has held numerous senior level financial an

Avian influenza, also known as bird flu, has public health officials on alert after it spread to an unprecedented number of cows in the U.S. this year and led to positive tests of the virus in four U.S. dairy workers so far this year. A severe variant of the H5N1 strain infected animals ranging from alpacas to house cats worldwide since 2020 and caused lethal outbreaks in commercial poultry, but this is the first year it has infected cows, Reuters reported. Humans have contracted different bird flu strains in Australia and Mexico, while different H5 subtypes have also shown up in other parts of the world including China and Cambodia. Most of the human cases have come from exposure t

As of July 9, 2024, two stocks in the materials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro. Here's the latest list of major overbought players in this sector. Balchem Corp (NASDAQ:BCPC) On May 3, Balchem posted better-than-expected first-quarter results.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Wedbush raised the price target for BJ’s Restaurants, Inc.  (NASDAQ:BJRI) from $40 to $43. Wedbush analyst Nick Setyan maintained an Outperform rating. BJ’s Restaurants shares rose 5.9% to close at $34.68 on Friday. See how other analysts view this stock. Mizuho boosted the price target for Robinhood Markets, Inc (NASDAQ:HOOD) from $20 to $21. Mizuho analyst Dan Dolev maintained a Buy rating. Robinhood shares rose 1.9% to close at $17.95 on Friday. See how other analysts view this stock. B of A

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Balchem (NASDAQ:BCPC) with a Buy and raises the price target from $167 to $170.

Balchem (NASDAQ:BCPC) reported quarterly earnings of $1.03 per share which beat the analyst consensus estimate of $0.99 by 4.04 percent. This is a 9.57 percent increase over earnings of $0.94 per share from the same period last year. The company reported quarterly sales of $239.66 million which beat the analyst consensus estimate of $232.46 million by 3.10 percent. This is a 3.06 percent increase over sales of $232.54 million the same period last year.

Balchem (NASDAQ:BCPC) reported quarterly earnings of $0.95 per share which beat the analyst consensus estimate of $0.93 by 2.15 percent. This is a 1.06 percent increase over earnings of $0.94 per share from the same period last year. The company reported quarterly sales of $228.70 million which missed the analyst consensus estimate of $234.66 million by 2.54 percent. This is a 1.65 percent decrease over sales of $232.53 million the same period last year.

Companies Reporting Before The Bell • Arbor Realty Trust (NYSE:ABR) is expected to report quarterly earnings at $0.44 per share on revenue of $97.65 million. • Liberty Broadband (NASDAQ:LBRDK) is projected to report quarterly earnings at $2.33 per share on revenue of $248.00 million. • Telephone and Data (NYSE:TDS) is estimated to report quarterly loss at $0.12 per share on revenue of $1.28 billion. • TC Energy (NYSE:TRP) is likely to report quarterly earnings at $1.09 per share on revenue of $4.21 billion. • United States Cellular (NYSE:USM) is projected to report quarterly earnings at $0.04 per share on revenue of $984.23 million. • Cinemark Hldgs (NYSE:CNK) is expected to report qua

Balchem (NASDAQ:BCPC) is set to give its latest quarterly earnings report on Friday, 2024-02-16. Here's what investors need to know before the announcement. Analysts estimate that Balchem will report an earnings per share (EPS) of $0.93. Balchem bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Past Earnings Performance Last quarter the company beat EPS by $0.07, which was followed by a 0.0% drop in the share price the next day. H

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Barclays increased AbbVie Inc. (NYSE:ABBV) price target from $160 to $170. Barclays analyst Carter Gould upgraded the stock from Equal-Weight to Overweight. AbbVie shares fell 4.3% to close at $138.93 on Friday. See how other analysts view this stock. JP Morgan cut the price target for Olin Corporation (NYSE:OLN) from $75 to $48. JP Morgan analyst Jeffrey Zekauskas downgraded the stock from Overweight to Neutral. Olin shares fell 9% to close at $42.12 on Friday. See how other analysts view this st

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Balchem (NASDAQ:BCPC) with a Buy and lowers the price target from $165 to $135.

4 - BALCHEM CORP (0000009326) (Issuer)

4 - BALCHEM CORP (0000009326) (Issuer)

4 - BALCHEM CORP (0000009326) (Issuer)

4 - BALCHEM CORP (0000009326) (Issuer)

4 - BALCHEM CORP (0000009326) (Issuer)

4 - BALCHEM CORP (0000009326) (Issuer)

4 - BALCHEM CORP (0000009326) (Issuer)

4 - BALCHEM CORP (0000009326) (Issuer)

4 - BALCHEM CORP (0000009326) (Issuer)

4 - BALCHEM CORP (0000009326) (Issuer)

HC Wainwright & Co. reiterated coverage of Balchem with a rating of Buy and set a new price target of $155.00 from $170.00 previously

Sidoti upgraded Balchem from Neutral to Buy and set a new price target of $175.00

HC Wainwright & Co. reiterated coverage of Balchem with a rating of Buy and set a new price target of $170.00 from $160.00 previously

Sidoti downgraded Balchem from Buy to Neutral and set a new price target of $175.00

Stephens & Co. downgraded Balchem from Overweight to Equal-Weight and set a new price target of $145.00 from $140.00 previously

HC Wainwright & Co. upgraded Balchem from to Buy and set a new price target of $160.00 from $145.00 previously

HC Wainwright reiterated coverage of Balchem with a rating of Buy and set a new price target of $145.00 from $126.00 previously

Stephens upgraded Balchem from Equal Weight to Overweight and set a new price target of $140.00 from $100.00 previously

Stephens & Co. upgraded Balchem from Equal-Weight to Overweight and set a new price target of $140.00 from $100.00 previously

Stephens upgraded Balchem from Equal-Weight to Overweight